A landmark clinical trial in anemia management, the TREAT study discusses the optimal hemoglobin levels that should be achieved in patients with chronic kidney disease. It’s results were surprising and have led to intense debate in the nephrology community as to the appropriate hemoglobin level, rate of rise, and method by which to increase hemoglobin.

See also: The CHOIR Trial and The CREATE Study

See also: Comparison of CREATE, CHOIR, and TREAT



**************************************
Estimated Time: 25 minutes
Target Audience: Fellows, Faculty
Title: Trial of Darbopoetin Alfa in Type 2 Diabetes and Chronic Kidney DIsease
Citation: The New England Journal of Medicine 2009, Volume 361, pp. 2019-32
Date Created: 2009
Revisions: None Indicated
Disclaimers: None Indicated
Resource Type: Text
Other: Presented at ECU Journal Club by Dr. Wafa Badwan on March 16, 2010
Recommend to a Colleague/Friend
**************************************






Transparent Peer Review



Please evaluate this teaching resource. Your evaluation will help future users discern quality teaching resources and help our authors improve the content on Nephrology On-Demand

GD Star Rating
loading...



To learn more about our 6-point transparent peer review system, click here



Trial of Darbopoeitin Alfa® in Type 2 Diabetes and Chronic Kidney Disease -- The TREAT Study, 8.5 out of 10 based on 1 rating
Share

Comments

More in CKD, General Nephrology (165 of 212 articles)